knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 01:06:16 - browse：6893

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： 2024 GOP presidential candidates spar over abortion in debate

leisure time

WSS

White House drug shortage group privately met with industry

Diversity in medical illustrations gets boost from Chidiebere Ibe

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Biden calls for immediate release of Niger's president amid apparent coup

Biden calls for immediate release of Niger's president amid apparent coup

Winners, losers from Medicare’s list of drugs subject to price talks

hotspot

knowledge

leisure time

Moonlake's readout produced a cash windfall. Risks remain

A cyberattack has disrupted hospitals and health care in several states

Novavax promises a turnaround & Lilly roils the obesity market

For BCIs, commercial hurdles may be bigger than scientific ones

Psychedelics group wrestles with new pharma identity

In science, is the line between industry and academia shifting?

At least 13 dead in Texas as scorching temps continue

TytoCare raises $49 million to build out AI

23andMe had bad news about my health. I wish a person had delivered it

White House drug shortage group privately met with industry

explore

Dramatically reducing cancer deaths requires the PASTEUR Act

What do new weight loss drugs mean for bariatric surgery?

Dramatically reducing cancer deaths requires the PASTEUR Act

Feds fine Medicare Advantage plans for overcharging members

Australia’s approach to dialysis celebrates life

Psilocybin's anti

explore

leisure time

hotspot

hotspot